Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
28
07
2023
accepted:
27
08
2024
revised:
21
08
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
20
9
2024
Statut:
aheadofprint
Résumé
Despite advances in diagnosis and treatment in lung cancer, therapies still fail to improve patient management due to resistance mechanisms and relapses. As Cancer stem cells (CSCs) directly contribute to tumor growth and therapeutic resistance, their clinical detection represents a major challenge. However specific and additional CSC markers lack. Thus, our aim was to achieve selective detection of CSCs with specific glycan patterns and assess the CSCs burden to predict the risk of relapse in NSCLC tumors. The lung CSCs detection and sorting with a lectin MIX were assessed and compared to CD133 in vitro. Then, its putative role as CSC biomarker was evaluated in vivo and its clinical significance on 221 NSCLC patients. We showed a significant CSCs enrichment in the MIX+ sorted fraction compared to CD133+ cells and confirmed its high tumorigenic capacity. The MIX prognostic value on the overall survival from early stages patients was validated suggesting its potential for detecting CSCs directly linked to tumor aggressiveness. The MIX could be more relevant for detecting and sorting CSCs than CD133. Moreover, its prognosis value could enable clinicians to better classify early-stage patients at high risk of relapse in order to tailor therapeutic decisions.
Sections du résumé
BACKGROUND
BACKGROUND
Despite advances in diagnosis and treatment in lung cancer, therapies still fail to improve patient management due to resistance mechanisms and relapses. As Cancer stem cells (CSCs) directly contribute to tumor growth and therapeutic resistance, their clinical detection represents a major challenge. However specific and additional CSC markers lack. Thus, our aim was to achieve selective detection of CSCs with specific glycan patterns and assess the CSCs burden to predict the risk of relapse in NSCLC tumors.
METHODS
METHODS
The lung CSCs detection and sorting with a lectin MIX were assessed and compared to CD133 in vitro. Then, its putative role as CSC biomarker was evaluated in vivo and its clinical significance on 221 NSCLC patients.
RESULTS
RESULTS
We showed a significant CSCs enrichment in the MIX+ sorted fraction compared to CD133+ cells and confirmed its high tumorigenic capacity. The MIX prognostic value on the overall survival from early stages patients was validated suggesting its potential for detecting CSCs directly linked to tumor aggressiveness.
CONCLUSION
CONCLUSIONS
The MIX could be more relevant for detecting and sorting CSCs than CD133. Moreover, its prognosis value could enable clinicians to better classify early-stage patients at high risk of relapse in order to tailor therapeutic decisions.
Identifiants
pubmed: 39304747
doi: 10.1038/s41416-024-02839-9
pii: 10.1038/s41416-024-02839-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.
doi: 10.1038/nrc3775
pubmed: 25056707
pmcid: 5712844
Bomken S, Fišer K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer. 2010;103:439–45.
doi: 10.1038/sj.bjc.6605821
pubmed: 20664590
pmcid: 2939794
Masciale V, Banchelli F, Grisendi G, D’Amico R, Maiorana A, Stefani A, et al. New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells. Front Oncol. 2021;11:613198.
doi: 10.3389/fonc.2021.613198
pubmed: 33868998
pmcid: 8047623
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5:288–300.
doi: 10.21037/tlcr.2016.06.07
pubmed: 27413711
pmcid: 4931124
Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3:242–9.
pubmed: 25806307
pmcid: 4367696
Suresh R, Ali S, Ahmad A, Philip PA, Sarkar FH. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Adv Exp Med Biol. 2016;890:57–74.
doi: 10.1007/978-3-319-24932-2_4
pubmed: 26703799
Halim NHA, Zakaria N, Satar NA, Yahaya BH. Isolation and Characterization of Cancer Stem Cells of the Non-Small-Cell Lung Cancer (A549) Cell Line. Methods Mol Biol Clifton NJ. 2016;1516:371–88.
doi: 10.1007/7651_2016_326
Miyata T, Yoshimatsu T, So T, Oyama T, Uramoto H, Osaki T, et al. Cancer stem cell markers in lung cancer. Pers Med Universe. 2015;4:40–45.
doi: 10.1016/j.pmu.2015.03.007
Maiuthed A, Chantarawong W, Chanvorachote P. Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds. Anticancer Res. 2018;38:3797–809.
doi: 10.21873/anticanres.12663
pubmed: 29970499
Zheng Y, Wang L, Yin L, Yao Z, Tong R, Xue J, et al. Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies. Front Oncol. 2022;12:873994.
doi: 10.3389/fonc.2022.873994
pubmed: 35719973
pmcid: 9204354
Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med Berl Ger. 2008;86:1025–32.
doi: 10.1007/s00109-008-0357-8
Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. Cancer Res. 2010;70:719–29.
doi: 10.1158/0008-5472.CAN-09-1820
pubmed: 20068153
Blondy S, Durand S, Lacroix A, Christou N, Bouchaud C, Peyny M, et al. Detection of Glycosylated Markers From Cancer Stem Cells With ColoSTEM Dx Kit for Earlier Prediction of Colon Cancer Aggressiveness. Front Oncol. 2022;12:918702.
doi: 10.3389/fonc.2022.918702
pubmed: 35936672
pmcid: 9355573
Guyon J, Fernandez-Moncada I, Larrieu CM, Bouchez CL, Pagano Zottola AC, Galvis J, et al. Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis. EMBO Mol Med. 2022;14:e15343.
doi: 10.15252/emmm.202115343
pubmed: 36278433
pmcid: 9728051
Codony-Servat J, Codony-Servat C, Cardona AF, Giménez-Capitán A, Drozdowskyj A, Berenguer J, et al. Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer. Clin Lung Cancer. 2019;20:167–77.
doi: 10.1016/j.cllc.2019.02.005
pubmed: 30885551
Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N. Immune responses to human cancer stem‐like cells/cancer‐initiating cells. Cancer Sci. 2016;107:12–17.
doi: 10.1111/cas.12830
pubmed: 26440127
Zhang C, Wang H, Wang X, Zhao C, Wang H. CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell Int. 2020;20:583.
doi: 10.1186/s12935-020-01671-4
pubmed: 33372595
pmcid: 7720536
Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev. 2010;29:61–72.
doi: 10.1007/s10555-010-9216-5
pubmed: 20094757
pmcid: 2864581
Zhang Y, Xu W, Guo H, Zhang Y, He Y, Lee SH, et al. NOTCH1 Signaling Regulates Self-Renewal and Platinum Chemoresistance of Cancer Stem–like Cells in Human Non–Small Cell Lung Cancer. Cancer Res. 2017;77:3082–91.
doi: 10.1158/0008-5472.CAN-16-1633
pubmed: 28416482
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci. 2009;106:16281–6.
doi: 10.1073/pnas.0905653106
pubmed: 19805294
pmcid: 2741477
Moro M, Bertolini G, Pastorino U, Roz L, Sozzi G. Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer. J Thorac Oncol. 2015;10:1027–36.
doi: 10.1097/JTO.0000000000000563
pubmed: 26020124
pmcid: 4467987
Akunuru S, James Zhai Q, Zheng Y. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 2012;3:e352.
doi: 10.1038/cddis.2012.93
pubmed: 22825470
pmcid: 3406592
Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133–43.
doi: 10.1038/nrc3184
pubmed: 22237392
Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. Therapy-induced enrichment of putative lung cancer stem-like cells. Int J Cancer. 2014;134:1270–8.
doi: 10.1002/ijc.28478
pubmed: 24105655
Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669–80.
doi: 10.1038/s41568-018-0056-x
pubmed: 30228301
pmcid: 8388042
Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer. 2010;126:950–8.
doi: 10.1002/ijc.24822
pubmed: 19676044
Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol Northwood Lond Engl. 2011;28:1458–62.
doi: 10.1007/s12032-010-9646-5
Boyd JA, Hubbs JL, Kim DW, Hollis D, Marks LB, Kelsey CR. Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure. J Thorac Oncol. 2010;5:211–4.
doi: 10.1097/JTO.0b013e3181c20080
pubmed: 19901853
Schegoleva AA, Khozyainova AA, Fedorov AA, Gerashchenko TS, Rodionov EO, Topolnitsky EB, et al. Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem. Cell Physiol Biochem. 2021;55:29–48.
doi: 10.33594/000000340
pubmed: 33687819
Barkeer S, Chugh S, Batra SK, Ponnusamy MP. Glycosylation of Cancer Stem Cells: Function in Stemness, Tumorigenesis, and Metastasis. Neoplasia NY N. 2018;20:813–25.
doi: 10.1016/j.neo.2018.06.001
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540–55.
doi: 10.1038/nrc3982
pubmed: 26289314
Lathia J, Liu H, Matei D. The Clinical Impact of Cancer Stem Cells. Oncologist. 2020;25:123–31.
doi: 10.1634/theoncologist.2019-0517
pubmed: 32043793